Recomendaciones SER-SEPAR para el manejo de la enfermedad pulmonar intersticial difusa asociada a la artritis reumatoide. Parte 2: tratamiento

Farquhar, 2019, Pulmonary complications of rheumatoid arthritis, Semin Respir Crit Care Med., 40, 194, 10.1055/s-0039-1683995 Yunt, 2015, Lung disease in rheumatoid arthritis, Rheum Dis Clin North Am., 41, 225, 10.1016/j.rdc.2014.12.004 Spagnolo, 2018, The lung in rheumatoid arthritis: Focus on interstitial lung disease, Arthritis Rheumatol., 70, 1544, 10.1002/art.40574 Bongartz, 2010, Incidence and mortality of interstitial lung disease in rheumatoid arthritis: A population-based study, Arthritis Rheum., 62, 1583, 10.1002/art.27405 Assayag, 2014, Predictors of mortality in rheumatoid arthritis-related interstitial lung disease, Respirology., 19, 493, 10.1111/resp.12234 Grupo de trabajo sobre GPC. Elaboración de Guías de Práctica Clínica en el Sistema Nacional de Salud. Manual Metodológico. Madrid: Plan Nacional para el SNS del MSC. Instituto Aragonés de Ciencias de la Salud-I+CS; 2007. Guías de Práctica Clínica en el SNS: I+CS N.° 2006/0I. NHS Scotland. 50: A guideline developers’ handbook. SIGN; 2011. Wells, 2019, Multidisciplinary evaluation in patients with lung disease associated with connective tissue disease, Semin Respir Crit Care Med., 40, 184, 10.1055/s-0039-1684020 Guía de práctica clínica para el manejo de pacientes con artritis reumatoide (GUIPCAR 2016-17) [consultado 3 Nov 2021]. Disponible en: https://www.ser.es/actualizacion-de-la-guia-guipcar/ Kremer, 1997, Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review, Arthritis Rheum., 40, 1829, 10.1002/art.1780401016 Li, 2020, A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease, Clin Rheumatol., 39, 1457, 10.1007/s10067-019-04846-1 Alarcón, 1997, Ann Intern Med., 127, 356, 10.7326/0003-4819-127-5-199709010-00003 Cannon, 1983, Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis, Arthritis Rheum., 26, 1269, 10.1002/art.1780261015 St Clair, 1985, Pneumonitis complicated low dose methotrexate therapy in rheumatoid arthritis, Arch Intern Med., 145, 2035, 10.1001/archinte.1985.00360110105023 Chikura, 2009, Clinical expression of leflunomide-induced pneumonitis, Rheumatology (Oxford)., 48, 1065, 10.1093/rheumatology/kep050 Roubille, 2014, Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: A systemaic literature review, Semin Arthritis Rheum., 43, 613, 10.1016/j.semarthrit.2013.09.005 Conway, 2014, Methotrexate and lung disease in rheumatoid arthritis: A meta-analysis of randomized controlled trials, Arthritis Rheumatol., 66, 803, 10.1002/art.38322 Kremer, 2020, Methotrexate pulmonary toxicity: Deep inspiration, Arthritis Rheumatol., 72, 1959, 10.1002/art.41451 Searles, 1987, Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature, J Rheumatol, 14, 1164 Conway, 2015, Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: Systematic literature review and meta-analysis of randomised controlled trials, BMJ., 350, h1269, 10.1136/bmj.h1269 Juge, 2021, Methotrexate and rheumatoid arthritis associated interstitial lung disease, Eur Respir J., 57, 2000337, 10.1183/13993003.00337-2020 Ibfelt, 2021, Methotrexate and risk of interstitial lung disease and respiratory failure in rheumatoid arthritis: A nationwide population-based study, Rheumatology (Oxford)., 60, 346, 10.1093/rheumatology/keaa327 Kiely, 2019, Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts, BMJ Open., 9, e028466, 10.1136/bmjopen-2018-028466 Solomon, 2020, Adverse effects of low-dose methotrexate: A randomized trial, Ann Intern Med., 172, 369, 10.7326/M19-3369 Sparks, 2020, Pulmonary adverse events in patients receiving low-dose methotrexate in the randomized, double-blind, placebo-controlled cardiovascular inflammation reduction trial, Arthritis Rheumatol., 72, 2065, 10.1002/art.41452 Ridker, 2019, Low-dose methotrexate for the prevention of atherosclerotic events, N Engl J Med., 380, 752, 10.1056/NEJMoa1809798 Rojas-Serrano, 2017, Rheumatoid arthritis-related interstitial lung disease (RA-ILD): Methotrexate and the severity of lung disease are associated to prognosis, Clin Rheumatol., 36, 1493, 10.1007/s10067-017-3707-5 Curtis, 2015, Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor α agents, a retrospective cohort study, Arthritis Res Ther., 17, 319, 10.1186/s13075-015-0835-7 Detorakis, 2017, Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents, Clin Exp Rheumatol., 35, 43 Cano-Jiménez, 2021, Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis, Sci Rep., 11, 9184, 10.1038/s41598-021-88734-2 Izuka, 2021, Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: Clinical features and prognosis, Rheumatology (Oxford)., 60, 2348, 10.1093/rheumatology/keaa608 Sparks, 2019, Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: A prospective cohort study, Arthritis Rheumatol., 71, 1472, 10.1002/art.40904 Robles-Pérez, 2020, A prospective study of lung disease in a cohort of early rheumatoid arthritis patients, Sci Rep., 10, 15640, 10.1038/s41598-020-72768-z Sawada, 2009, Leflunomide-induced interstitial lung disease: prevalence and risk factors in Japanese patients with rheumatoid arthritis, Rheumatology (Oxford)., 4, 1069, 10.1093/rheumatology/kep052 Ju, 2007, Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis, Arthritis Rheum., 56, 2094, 10.1002/art.22666 Suissa, 2006, Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis, Arthritis Rheum., 54, 1435, 10.1002/art.21806 Conway, 2016, Leflunomide use and risk of lung disease in rheumatoid arthritis: a systematic literature review and metaanalysis of randomized controlled trials, J Rheumatol., 43, 855, 10.3899/jrheum.150674 Fernández-Díaz, 2020, Abatacept in interstitial lung disease associated with rheumatoid arthritis: National multicenter study of 263 patients, Rheumatology (Oxford), 59, 3906, 10.1093/rheumatology/keaa621 Narváez, 2020, Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease, Semin Arthritis Rheum., 50, 902, 10.1016/j.semarthrit.2020.08.008 Vadillo, 2020, Efficacy of rituximab in slowing down progression of rheumatoid arthritis-related interstitial lung disease: Data from the NEREA Registry, Rheumatology (Oxford)., 59, 2099, 10.1093/rheumatology/kez673 Mena-Vázquez, 2021, Non-anti-TNF biologic agents are associated with slower worsening of interstitial lung disease secondary to rheumatoid arthritis, Clin Rheumatol., 40, 133, 10.1007/s10067-020-05227-9 Manfredi, 2020, Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: A multicentre retrospective Study, Intern Med J., 50, 1085, 10.1111/imj.14670 Cassone, 2020, Safety of abatacept in italian patients with rheumatoid arthritis and interstitial lung disease: A multicenter retrospective study, J Clin Med., 9, 277, 10.3390/jcm9010277 Yusof, 2017, Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years’ experience at a single centre, Rheumatology (Oxford)., 56, 1348, 10.1093/rheumatology/kex072 Jani, 2014, The safety of biologic therapies in RA-associated interstitial lung disease, Nat Rev Rheumatol., 10, 284, 10.1038/nrrheum.2013.197 Pérez Alvarez, 2011, Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases, Semin Arthritis Rheum., 41, 256, 10.1016/j.semarthrit.2010.11.002 Hadjinicolaou, 2011, Non-infectious pulmonary complications of newer biological agents for rheumatic-diseases. A systematic literature review, Rheumatology (Oxford)., 50, 2297, 10.1093/rheumatology/ker289 Nakashita, 2014, Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis, BMJ Open., 4, e005615, 10.1136/bmjopen-2014-005615 Dixon, 2010, Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: Results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis., 69, 1086, 10.1136/ard.2009.120626 Koo, 2015, Mortality in patients with rheumatoid arthritis-associated interstitial lung disease treated with an anti-tumor necrosis factor agent, Korean J Intern Med., 30, 104, 10.3904/kjim.2015.30.1.104 Yousem, 2005, Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy, Mod Pathol., 18, 651, 10.1038/modpathol.3800333 Gifre, 2011, Sarcoidosis pulmonar inducida por antagonistas del factor de necrosis tumoral en la artritis reumatoide: Presentación de un caso y revisión de la literatura médica, Arch Bronconeumol., 47, 208, 10.1016/j.arbres.2010.05.011 Herrinton, 2013, Association between anti-TNF α therapy and interstitial lung disease, Pharmacoepidemiol Drug Sat., 22, 394, 10.1002/pds.3409 Wolfe, 2007, Rheumatoid arthritis treatment and the risk of severe interstitial lung disease, Scand J Rheumatol., 36, 172, 10.1080/03009740601153774 Druce, 2017, Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic, RMD Open., 3, e000473, 10.1136/rmdopen-2017-000473 Garcia Vicuña, 2005, Inflammatory interstitial lung disease in rheumatoid arthritis patients treated with biologic treatment. Incidence and mortality rates compared with patients non receiving biologics [Abstract], Ann Rheum Dis., 64, 470 Wendling, 2013, Exacerbation of combined pulmonary fibrosis and emphysema syndrome during tocilizumab therapy for rheumatoid arthritis, Joint Bone Spine., 80, 670, 10.1016/j.jbspin.2013.03.009 Kawashiri, 2012, A fatal case of acute exacerbation of interstitial lung disease in a patients with rheumatoid arthritis during treatment with tocilizumab, Rheumatol Int., 32, 4023, 10.1007/s00296-010-1525-z Koike, 2014, Effectiveness and safety of tocilizumab: Postmarketing surveillance of 7901 patients with rheumatoid arthritis in Japan, J Rheumatol., 41, 15, 10.3899/jrheum.130466 Akiyama, 2016, Association of disease activity with acute exacerbation of interstitial lung disease during tocilizumab treatment in patients with rheumatoid arthritis: A retrospective, case-control study, Rheumatol Int., 36, 881, 10.1007/s00296-016-3478-3 Mohr, 2011, Interstitial lung disease in rheumatoid arthritis: response to IL-6R blockade, Scand J Rheumatol., 40, 400, 10.3109/03009742.2011.599072 Picchianti Diamanti, 2017, Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review, Ther Adv Respir Dis., 11, 64, 10.1177/1753465816668780 Guía de práctica clínica para el manejo de pacientes con artritis reumatoide (GUIPCAR 2016-17) [consultado 3 Nov 2021]. Disponible en: https://www.ser.es/actualizacion-de-la-guia-guipcar/ Holroyd, 2019, The British Society for Rheumatic biologic DMARD safety guidelines in inflammatory arthritis, Rheumatology., 58, 372, 10.1093/rheumatology/key298 Doğu, 2016, A case of acute respiratory failure in a rheumatoid arthritis patient after the administration of abatacept, Eur J Rheumatol., 3, 134, 10.5152/eurjrheum.2015.0037 Wada, 2012, A case of rheumatoid arthritis complicated with deteriorated interstitial pneumonia after the administration of abatacept, Nihon Rinsho Meneki Gakkai Kaishi., 35, 433, 10.2177/jsci.35.433 Weinblatt, 2013, Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: Integrated analyses of up to 8 years of treatment from the abatacept clinical trial program, J Rheumatol., 40, 787, 10.3899/jrheum.120906 Nakashita, 2016, Possible effect of abatacept on the progression of interstitial lung disease in rheumatoid arthritis patients, Respir Investig., 54, 376, 10.1016/j.resinv.2016.03.001 Mochizuki, 2019, Long-term deterioration of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept, Mod Rheumatol., 29, 413, 10.1080/14397595.2018.1481566 Matteson, 2012, Open-label, pilot study of the safety and clinical effects of rituximab in patients with rheumatoid arthritis-associated interstitial pneumonia, Open J Rheumatol Autoimmune Dis., 2, 53, 10.4236/ojra.2012.23011 Fui, 2020, Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis, Intern Med J., 50, 330, 10.1111/imj.14306 Duarte, 2019, The lung in a cohort of rheumatoid arthritis patients — an overview of different types of involvement and treatment, Rheumatology (Oxford)., 58, 2031, 10.1093/rheumatology/kez177 Gottenberg, 2010, Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and Rituximab registry, Arthritis Rheum., 62, 2625, 10.1002/art.27555 Citera, 2020, Incidence rates of interstitial lung disease events in tofacitinib-treated rheumatoid arthritis patients: Post hoc analysis from 21 clinical trials, J Clin Rheumatol Khoo, 2020, Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: Systematic review and meta-analysis, Rheumatology (Oxford)., 59, 2217, 10.1093/rheumatology/keaa117 Saldarriaga-Rivera, 2019, Janus kinase inhibitors as a therapeutic option in rheumatoid arthritis and associated interstitial lung disease. Report of four cases, Rev Colomb Reumatol., 26, 137 Salvarani, 2021, Baricitinib and the risk of incident interstitial lung disease: A descriptive clinical case report from clinical trials, Rheumatol Ther., 8, 1435, 10.1007/s40744-021-00332-w Zamora-Legoff, 2016, Risk of serious infection in patients with rheumatoid arthritis-associated interstitial lung disease, Clin Rheumatol., 35, 2585, 10.1007/s10067-016-3357-z Del Rincón, 2014, Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis, Arthritis Rheumatol., 66, 264, 10.1002/art.38210 Sanmartí, 2020, Efficacy and safety of glucocorticoids in rheumatoid arthritis: Systematic literature review, Reumatol Clin., 16, 222, 10.1016/j.reuma.2018.06.007 Roubille, 2015, The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: A systematic review and meta-analysis, Ann Rheum Dis., 74, 480, 10.1136/annrheumdis-2014-206624 Daien, 2017, Non-pharmacological and pharmacological interventions in patients with early arthritis: A systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis, RMD Open., 3, e000404, 10.1136/rmdopen-2016-000404 Panettieri, 2019, Nongenomic effects of glucocorticoids: an updated view, Trends Pharmacol Sci., 40, 38, 10.1016/j.tips.2018.11.002 Vandewalle, 2018, Therapeutic mechanisms of glucocorticoids, Trends Endocrinol Metab., 29, 42, 10.1016/j.tem.2017.10.010 Saketkoo, 2008, Rheumatoid arthritis interstitial lung disease: Mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug, Arch Intern Med., 168, 1718, 10.1001/archinte.168.15.1718 Puttick, 1995, Treatment of progressive rheumatoid interstitial lung disease with cyclosporine, J Rheumatol., 22, 2163 Chang, 2002, Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: A case report, J Korean Med Sci., 17, 270, 10.3346/jkms.2002.17.2.270 Ogawa, 2000, Successful use of cyclosporinA for the treatment of acute interstitial pneumonitis associated with rheumatoid arthritis, Rheumatology (Oxford)., 39, 1422, 10.1093/rheumatology/39.12.1422 Rojas-Serrano, 2012, Interstitial lung disease related to rheumatoid arthritis: Evolution after treatment, Reumatol Clin., 8, 68, 10.1016/j.reuma.2011.12.008 Cohen, 1977, Interstitial pneumonitis complicating rheumatoid arthritis. Sustained remission with azathioprine therapy, Chest., 72, 521, 10.1378/chest.72.4.521 Li, 2020, A retrospective study on the predictive implications of clinical characteristics and therapeutic management in patients with rheumatoid arthritis-associated interstitial lung disease, Clin Rheumatol., 39, 1457, 10.1007/s10067-019-04846-1 Ota, 2017, Efficacy of intensive immunosuppression in exacerbated rheumatoid arthritis-associated interstitial lung disease, Mod Rheumatol., 27, 22, 10.3109/14397595.2016.1173816 Suwa, 1999, Rheumatoid arthritis associated with methotrexate-induced pneumonitis: Improvement with i.v. cyclophosphamide therapy, Clin Exp Rheumatol., 17, 355 Schupp, 2016, Usefulness of cyclophosphamide pulse therapy in interstitial lung diseases, Respiration., 91, 296, 10.1159/000445031 Tokano, 2002, CyclosporinA therapy for interstitial pneumonitis associated with rheumatic disease, Mod Rheumatol., 12, 305, 10.3109/s101650200054 Fischer, 2013, Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease, J Rheumatol., 40, 640, 10.3899/jrheum.121043 Oldham, 2016, Azathioprine response in patients with fibrotic connective tissue disease-associated interstitial lung disease, Respir Med., 121, 117, 10.1016/j.rmed.2016.11.007 Kelly, 2021, Rheumatoid arthritis related interstitial lung disease — improving outcomes over 25 years: A large multicentre UK study, Rheumatology (Oxford)., 60, 1882, 10.1093/rheumatology/keaa577 Fernández-Díaz, 2021, Abatacept in monotherapy versus combined in interstitial lung disease of rheumatoid arthritis. Multicenter study of 263 Caucasian patients, Rheumatology (Oxford)., 61, 299, 10.1093/rheumatology/keab317 Kurata, 2019, Effect of biological disease-modifying anti-rheumatic drugs on airway and interstitial lung disease in patients with rheumatoid arthritis, Intern Med., 58, 1703, 10.2169/internalmedicine.2226-18 Ficha técnica de nintedanib [consultado 3 Nov 2021]. Disponible en: https://cima.aemps.es/cima/dochtml/ft/114979004/FT_114979004.html Flaherty, 2019, Nintedanib in progressive fibrosing interstitial lung diseases, N Engl J Med., 381, 1718, 10.1056/NEJMoa1908681 Wells, 2020, Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: A randomised, double-blind, placebo-controlled, parallel-group trial, Lancet Respir Med., 8, 453, 10.1016/S2213-2600(20)30036-9 Matteson, 2019, Effect of nintedanib on progression of interstitial lung disease (ILD) in patients with autoimmune disease-related ILDs: Further data from the INBUILD trial [abstract 374], Arthritis Rheumatol., 71 Tashkin, 2006, Cyclophosphamide versus placebo in scleroderma lung disease, N Engl J Med., 354, 2655, 10.1056/NEJMoa055120 Tashkin, 2016, Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): A randomised controlled, double-blind, parallel group trial, Lancet Respir Med., 4, 708, 10.1016/S2213-2600(16)30152-7